98%
921
2 minutes
20
Objective: Vulvar lichen sclerosus (VLS) is a chronic inflammatory skin condition characterized by whitening of the external genitalia, debilitating pruritus (itching), and pain. As disease advances, loss of labia, burying of vulvar anatomy (ie, clitoris, urethra, vaginal opening), and vulvar cancer can occur, yet mechanistic understanding of these events remains limited. VLS lesions appear visibly similar to scars and are frequently referred to as such. Therefore, we investigated the role of fibrosis in the VLS disease mechanism with the goal of identifying targets for new therapeutic and diagnostic strategies.
Study Design: 6-mm biopsies were collected from 8 participants with VLS from regions of the vulva visibly affected by lichen sclerosus ("scarred") and adjacent unaffected areas ("unscarred"), allowing each patient to serve as their own control thus diminishing biological noise. Specimens were also used to establish fibroblast strains, and cells were stimulated with TGF-β to assess fibroblast-to-myofibroblast transitions, extracellular matrix (ECM) production, and inflammatory responses in scarred versus unscarred areas.
Results: Fibroblasts from scarred areas expressed higher levels of cytoskeletal proteins (alpha-smooth muscle actin) and inflammatory mediators (interleukin 6, prostaglandin E2) upon TGF-β stimulation compared to their unscarred counterparts. Treatment with SB-431542, a TGF-β receptor inhibitor, quelled these responses (≤.05), indicating that these effects are mediated through the TGF-β pathway. Fibroblasts isolated from scarred tissues exhibit myofibroblast morphologies, but so do fibroblasts from unscarred areas.
Conclusion: TGF-β activates myofibroblasts and exacerbates inflammation in VLS cells from scarred areas. However, fibroblasts from both scarred and unscarred areas show similarities in morphology and ECM production, suggesting molecular changes may occur in VLS skin before visible changes are detected, which could lead to new diagnostic strategies to treat disease before irreversible architectural changes occur.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12271616 | PMC |
http://dx.doi.org/10.1016/j.xagr.2025.100528 | DOI Listing |
BMJ Open
September 2025
University of Birmingham, Birmingham, UK.
Objective: To explore experience and prevalence of vulval lichen sclerosus (VLS) diagnosis in general practice using an anonymous patient survey.
Design: Quantitative descriptive cross-sectional survey informed by previous qualitative interviews and developed with patient representatives, sent to people recorded in general practice as having a VLS diagnosis.
Setting: General practices (n=24) in the UK (West Midlands).
JMIR Res Protoc
September 2025
Discipline of Biomedical Engineering, School of Electrical and Mechanical Engineering, University of Adelaide, Adelaide, Australia.
Background: Vulvar lichen sclerosus (LS) is a chronic relapsing dermatosis commonly affecting the anogenital region in postmenopausal women, though it can affect people of any age and sex. The current gold standard treatment is lifelong topical steroid application to reduce symptoms and prevent the progression of disease, causing irreversible architectural change to the vulval tissue. LS is associated with decreased quality of life and increased risk of vulvar neoplasia.
View Article and Find Full Text PDFJ Invest Dermatol
August 2025
Department of Biological Chemistry, School of Medicine; Department of Dermatology, School of Medicine. Electronic address:
Vulvar diseases are a neglected area of women's health, profoundly affecting patients' quality of life. Lichen sclerosus (LS) is a chronic inflammatory vulvar skin disorder leading to severe itching, pain, scarring, and an increased risk of malignancy. Despite this burden, the molecular pathogenesis of vulvar LS (VLS) is not well understood, limiting treatment options.
View Article and Find Full Text PDFJ Clin Med
August 2025
Discipline of Biomedical Engineering, School of EME, The University of Adelaide, Adelaide, SA 5005, Australia.
Platelet-rich plasma (PRP) therapy is a non-invasive, autologous treatment with regenerative potential in gynaecology beyond fertility applications. This review evaluates PRP in non-fertility-related gynaecological conditions affecting women's quality of life (QoL). Following PRISMA-ScR guidelines, we searched Embase, CINAHL, Web of Science, Scopus, CENTRAL, and MEDLINE for studies on PRP in conditions such as vulvar lichen sclerosus (VLS), vulvovaginal atrophy (VVA), sexual dysfunction (SD), stress urinary incontinence (SUI), and interstitial cystitis/bladder pain syndrome (IC/BPS).
View Article and Find Full Text PDFIndian Dermatol Online J
September 2025
Department of Dermatology and Venereology, Kasturba Medical College Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Vulvar neoplasia is on the rise and patients often present to dermatologists with lesions of varying morphology associated with pruritus, burning sensation, or pain. Early diagnosis results in an early treatment and improved quality of life. Differentiating vulvar neoplasia and intraepithelial malignancies from benign and inflammatory conditions is imperative.
View Article and Find Full Text PDF